Company Analysis
Sign in

Opus Genetics, Inc. (IRD)

Nasdaq: IRD · Pharmaceutical Preparations · Durham, NC · filing with the SEC since 2003
Full chart Alerts Compare
Grade4.4
◀ Past 4.3● Present 2.3▶ Future 6.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

35 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Opus Genetics, Inc.’s names, not what it holds today.

Patents granted
35
35 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 3 in 2023
Applications published
48
6 of them in 2025
Names they are printed under
6
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
REXAHN PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
19 granted
18 published
Ocuphire Pharma, Inc. a former name
named as the applicant on its applications, in US
0 granted
20 published
Ocuphire Pharma, Inc. a former name
US, as the owner printed on each patent
11 granted
0 published
Opus Genetics, Inc. its own name
named as the applicant on its applications, in US
0 granted
6 published
Opus Genetics, Inc. its own name
US, as the owner printed on each patent
5 granted
0 published
Rexahn Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 8, 202512,350,366Aqueous ophthalmic solutions of phentolamine and medical uses thereofPharmaceuticalsOpus Genetics, Inc.
May 27, 202512,312,308Salts and esters of APX3330 and therapeutic uses thereofOrganic fine chemistryOpus Genetics, Inc.
Jan 21, 202512,201,616Methods and compositions for treatment of mydriasisPharmaceuticalsOpus Genetics, Inc.
Jan 21, 202512,201,615Methods and compositions for treatment of mydriasisPharmaceuticalsOpus Genetics, Inc.
Dec 10, 202412,161,629Methods and compositions for treatment of glaucoma and related conditionsPharmaceuticalsOpus Genetics, Inc.
Jun 25, 202412,016,841Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disordersPharmaceuticalsOcuphire Pharma, Inc.
May 7, 202411,976,044Highly pure phentolamine mesylateOrganic fine chemistryOcuphire Pharma, Inc.
Dec 19, 202311,844,858Aqueous ophthalmic solutions of phentolamine and medical uses thereofPharmaceuticalsOcuphire Pharma, Inc.
Aug 8, 202311,717,510Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performancePharmaceuticalsOcuphire Pharma, Inc.
Jan 31, 202311,566,005Highly pure phentolamine mesylate and methods for making sameOrganic fine chemistryOcuphire Pharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 21, 20252025/0262149AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOFPharmaceuticalsOpus Genetics, Inc.
Aug 7, 20252025/0248931AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOFPharmaceuticalsOpus Genetics, Inc.
Aug 7, 20252025/0248930AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOFPharmaceuticalsOpus Genetics, Inc.
May 22, 20252025/0162995PHENTOLAMINE MESYLATE AND THERAPEUTIC USES THEREOFPharmaceuticalsOpus Genetics, Inc.
May 22, 20252025/0161275METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISPharmaceuticalsOpus Genetics, Inc.
May 22, 20252025/0161274METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISPharmaceuticalsOpus Genetics, Inc.
Sep 19, 20242024/0308967HIGHLY PURE PHENTOLAMINE MESYLATE AND METHODS FOR MAKING SAMEOrganic fine chemistryOcuphire Pharma, Inc.
Aug 29, 20242024/0285519AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOFPharmaceuticalsOcuphire Pharma, Inc. · patent 12,350,366 granted from it
Jul 4, 20242024/0216334METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULARCONDITIONSPharmaceuticalsOcuphire Pharma, Inc.
Jul 4, 20242024/0216315METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETIC RETINOPATHY AND RELATED CONDITIONSPharmaceuticalsOcuphire Pharma, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 10 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IRD · research, not advice